Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization -105% Improvement Relative Risk Favipiravir  Vaezi et al.  EARLY TREATMENT  DB RCT Is early treatment with favipiravir beneficial for COVID-19? Double-blind RCT 77 patients in Iran (December 2020 - March 2021) Higher hospitalization with favipiravir (not stat. sig., p=0.43) Vaezi et al., Advances in Respiratory .., Jan 2023 Favors favipiravir Favors control

Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial

Vaezi et al., Advances in Respiratory Medicine, doi:10.3390/arm91010004, IRCT20171219037964N3
Jan 2023  
  Source   PDF   All   Meta
RCT 77 outpatients in Iran, showing increased hospitalization with treatment, without statistical significance. Favipiravir 1600mg daily for five days. 21% of favipiravir patients did not complete treatment.
risk of hospitalization, 105.3% higher, RR 2.05, p = 0.43, treatment 4 of 38 (10.5%), control 2 of 39 (5.1%), day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Vaezi et al., 28 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 6 authors, study period 5 December, 2020 - 31 March, 2021, trial IRCT20171219037964N3. Contact: (corresponding author).
This PaperFavipiravirAll
Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial
Atefeh Vaezi, Mehrzad Salmasi, Forogh Soltaninejad, Mehrdad Salahi, Shaghayegh Haghjooy Javanmard, Babak Amra
Advances in Respiratory Medicine, doi:10.3390/arm91010004
What are the main findings? • Favipiravir, an RNA-dependent RNA polymerase inhibitor, shows no benefit in preventing the hospitalization of mild to moderate COVID-19 patients. What is the implication of the main finding? • Our results may inform decisions on the exclusion of Favipiravir from mild to moderate COVID-19 treatment guidelines.
Informed Consent Statement: Patients were informed about the study protocol and objectives and were asked to sign an informed consent before participation. All data were managed, analyzed, and reported anonymously. Medications were provided by the research team and imposed no costs on patients. Conflicts of Interest: The authors declare that they have no conflict of interest.
Alqahtani, Kumar, Aljawder, Abdulrahman, Mohamed et al., Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease, Sci. Rep, doi:10.1038/s41598-022-08794-w
Baranovich, Wong, Armstrong, Marjuki, Webby et al., T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro, J. Virol, doi:10.1128/JVI.02346-12
Bosaeed, Alharbi, Mahmoud, Alrehily, Bahlaq et al., Efficacy of favipiravir in adults with mild COVID-19: A randomized, double-blind, multicentre, placebocontrolled clinical trial, Clin. Microbiol. Infect, doi:10.1016/j.cmi.2021.12.026
Bryant, Lawrie, Fordham, Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, Am. J. Ther, doi:10.1097/MJT.0000000000001402
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering, doi:10.1016/j.eng.2020.03.007
Darab, Keshavarz, Sadeghi, Shahmohamadi, Kavosi, The economic burden of coronavirus disease 2019 (COVID-19): Evidence from Iran, BMC Health Serv. Res
Deng, Yang, Yang, Chen, Qiu et al., Evaluation of favipiravir in the treatment of COVID-19 based on the real-world, Expert Rev. Anti-Infect. Ther, doi:10.1080/14787210.2022.2012155
Dessie, Zewotir, Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients, BMC Infect. Dis, doi:10.1186/s12879-021-06536-3
Frediansyah, Nainu, Dhama, Mudatsir, Harapan, Remdesivir and its antiviral activity against COVID-19: A systematic review, Clin. Epidemiology Glob. Health, doi:10.1016/j.cegh.2020.07.011
Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antivir. Res, doi:10.1016/j.antiviral.2013.09.015
Gonçalves, Bertrand, Ke, Comets, De Lamballerie et al., Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. CPT Pharmacomet, Syst. Pharmacol, doi:10.1002/psp4.12543
Goyal, Cardozo-Ojeda, Schiffer, Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response, Sci. Adv, doi:10.1126/sciadv.abc7112
Hassaniazad, Farshidi, Gharibzadeh, Bazram, Khalili et al., Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial, J. Med. Virol, doi:10.1002/jmv.27724
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials, Sci. Rep
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin. Infect. Dis
Joshi, Parkar, Ansari, Vora, Talwar et al., Role of favipiravir in the treatment of COVID-19, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.10.069
Khamis, Al Naabi, Al Lawati, Ambusaidi, Al Sharji et al., Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.008
Kow, Ramachandram, Hasan, Future of antivirals in COVID-19: The case of favipiravir, Int. Immunopharmacol, doi:10.1016/j.intimp.2021.108455
Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy et al., Repurposed Antiviral Drugs for COVID-19-Interim WHO Solidarity Trial Results, N. Engl. J. Med
Reddy, Patil, Khobragade, Balki, Raj et al., Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting, Int. J. Gen. Med, doi:10.2147/IJGM.S349241
Schulz, Altman, Moher, Consort, statement: Updated guidelines for reporting parallel group randomised trials, J. Pharmacol. Pharmacother, doi:10.4103/0976-500X.72352
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: A rapid systematic review and meta-analysis, Virol. J, doi:10.1186/s12985-020-01412-z
Sirijatuphat, Manosuthi, Niyomnaitham, Owen, Copeland et al., Early treatment of Favipiravir in COVID-19 patients without pneumonia: A multicentre, open-labelled, randomized control study, Emerg. Microbes Infect, doi:10.1080/22221751.2022.2117092
Solaymani-Dodaran, Ghanei, Bagheri, Qazvini, Vahedi et al., Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, Int. Immunopharmacol, doi:10.1016/j.intimp.2021.107522
Soy, Keser, Atagündüz, Tabak, Atagündüz et al., Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment, Clin. Rheumatol, doi:10.1007/s10067-020-05190-5
Worldometer, COVID-19 Pandemic
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop